Pregnant Pause: First Phase III Data Hint At Improved Success For ObsEva IVF Drug

Top-line data for the IVF drug look promising but what investors really want to see are the Phase III data for ObsEva's lead product expected later this year in the much larger uterine fibroid market.

Egg — Hopes for higher success rates in IVF • Source: Shutterstock

ObsEva SA's oral oxytocin inhibitor nolasiban may be able to increase the chances of a successful pregnancy following IVF treatment, suggest top-line Phase III data. The company claims the product (previously known as OBE001) could be one of the biggest leaps forward in infertility treatment in decades but more studies are needed before it is likely to reach the market.

Initial results from the IMPLANT2 study show an increase in ongoing pregnancy rate at week 10 in patients undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICIS) when given as a single...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.